Post-earnings recap
Reported
Thu, Nov 3, 2016
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
CytomX Therapeutics reported a larger-than-expected loss per share, which contributed to a 2.75% decline in the stock price. Investors may be concerned about the lack of revenue details and the absence of guidance, leading to uncertainty about the company's future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.40 | N/A | -14.29% |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based solely on numerical results.